Semaglutide

Synonimy: Semaglutide, GLP-1 (7-37) analog, NN9535, NNC 0113-0217, Ozempic, Wegovy, Rybelsus, GLP-1 receptor agonist

In the rapidly evolving landscape of metabolic therapeutics, few molecules have captured the attention of both the scientific community and the pharmaceutical industry as intensely as semaglutide. As a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, it has redefined treatment paradigms for type 2 diabetes and obesity, and ongoing research continues to explore its potential in cardiovascular health, neurodegenerative conditions, and beyond. For procurement professionals and formulation scientists, semaglutide represents not just a therapeutic breakthrough but a strategic ingredient with robust and growing market demand.

Semaglutide is a synthetic analog of human GLP-1, engineered to resist degradation by dipeptidyl peptidase-4 (DPP-4) and to bind more tightly to albumin, which extends its half-life to approximately one week. This allows for once-weekly subcutaneous dosing or once-daily oral administration, a significant advantage over native GLP-1 and earlier analogs. The peptide is produced via recombinant technology or solid-phase peptide synthesis, followed by rigorous purification to achieve high purity suitable for pharmaceutical use.

At LyvBio, we supply semaglutide with a guaranteed purity of ≥98% (HPLC), ensuring consistent quality for further manufacturing, research, or compounding. Our material is characterized by low moisture content, minimal impurities, and batch-to-batch reproducibility, making it an ideal choice for clients developing generic or biosimilar products, conducting clinical trials, or formulating innovative therapies.

Product Overview & Composition

Semaglutide is a 31-amino acid peptide with a molecular formula of C187H291N45O59 and a molecular weight of 4113.58 g/mol. Its structure incorporates several key modifications: an Aib substitution at position 8, a diacidic linker at Lys26, and a C18 fatty acid chain that facilitates albumin binding. These modifications confer resistance to DPP-4 cleavage and a prolonged half-life. The peptide is typically supplied as a white to off-white lyophilized powder, which is stable and easy to handle.

Our semaglutide is produced under strict quality control measures, including rigorous testing for purity, identity, and residual solvents. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) to ensure compliance with industry standards.

Key Applications

• Type 2 Diabetes Management: Semaglutide improves glycemic control by enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
• Obesity Treatment: It reduces appetite and food intake, leading to significant weight loss, and is approved for chronic weight management.
• Cardiovascular Risk Reduction: Clinical trials have shown semaglutide reduces major adverse cardiovascular events in high-risk patients.
• Research and Development: Used as a reference standard or active ingredient in preclinical and clinical studies exploring novel GLP-1-based therapies.
• Compounding and Formulation: Suitable for pharmacies and manufacturers developing custom formulations, such as injectables or oral tablets.

Quality & Standards

Packaging & Supply

• Opakowanie: Supplied in amber glass vials or aseptic bags, sealed under nitrogen, with desiccant.
• MOQ: 1 gram (custom quantities available upon request).
• Czas realizacji: 3–5 dni roboczych (towary dostępne w magazynie)
• Dokumentacja: COA, MSDS, TDS, and stability data provided upon request.

Zapytanie ofertowe

• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com